Three-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry.
Deborah N KalkmanLaura S KerkmeijerPier WoudstraIan B A MenownHarry SuryapranataPeter den HeijerAndrés Iñiguez RomoArnoud W J van 't HofAndrejs ErglisKarin E ArkenboutPhilippe MullerKarel T KochJan G TijssenMarcel A M BeijkRobbert J de WinterPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2018)
The COMBO stent is a sirolimus-eluting stent with a luminal anti-CD34-antibody layer, that binds endothelial progenitor cells. These cells can differentiate to endothelial cells and stimulate early endothelialization of the stent. The REMEDEE Registry is the first large, multicenter, prospective, cohort study evaluating the clinical outcomes of 1,000 all-comers patients treated with COMBO stent. Target lesion failure at 3 year follow-up was 10.7% and the rate of definite ST was 0.7%.